Core Viewpoint - Cloudbreak Pharma Inc. (referred to as "Cloudbreak") has submitted a prospectus to the Hong Kong Stock Exchange for a proposed listing on the main board, marking its third attempt after previous applications lapsed [2]. Company Overview - Established in 2015, Cloudbreak is an innovative clinical-stage ophthalmic biotechnology company focused on developing novel and differentiated therapies. The company has built a pipeline of eight candidate drugs targeting major diseases of the anterior and posterior segments of the eye, with four in clinical stages and four in preclinical stages [3][4]. Product Pipeline - Clinical-stage candidates include: - CBT-001 and CBT-004, potentially the world's first treatments for pterygium and vascularized eyelid lesions, respectively. - CBT-006, aimed at treating meibomian gland dysfunction-related dry eye, is a potential first-in-class drug. - CBT-009, a potential best-in-class treatment for juvenile myopia. - Preclinical candidates include: - CBT-007, which aims to improve the success rate of glaucoma filtration surgery. - CBT-145 and CBT-199, new chemical entities for treating presbyopia. - CBT-011, an antibody-drug conjugate for diabetic macular edema [4]. Shareholder Structure - Prior to the IPO, the shareholder structure includes: - Dr. Ni Jinsong and Ms. Bing Leng holding approximately 20.86% and 1.32%, respectively, totaling 22.18%. - Other significant shareholders include Van Son Dinh (7.39%), Yang Rong (1.76%), and various investment firms and trusts [6][7]. Management Team - The board of directors consists of nine members, including: - Executive directors: Dr. Ni Jinsong (Chairman and CEO), Van Son Dinh (COO), and Dr. Yang Rong (CSO). - Non-executive and independent directors contribute to governance and oversight [9][11]. Financial Performance - Cloudbreak has reported no revenue in the past years, with R&D expenses increasing from $8.46 million in 2021 to $27.49 million in 2023. The net losses for the same periods were $35.40 million, $66.84 million, and $129.42 million, respectively [10][12]. IPO Advisory Team - The IPO advisory team includes UBS, CCB International, and Huatai International as joint sponsors, with PwC as the auditor. Legal counsel is provided by various firms for different jurisdictions [10].

Core Viewpoint - The China Securities Regulatory Commission has approved the overseas listing of Bokan Vision on the Hong Kong Stock Exchange, with plans to issue up to 133 million shares. The company is a clinical-stage ophthalmic biotech firm focused on developing therapies for eye diseases [1]. Financial Performance - Bokan Vision has not yet commercialized any products and has been operating at a loss since its inception. The losses from 2021 to June 2024 are reported as $35.398 million, $66.838 million, $129 million, and $52.111 million, respectively. Cumulatively, the losses have reached $309 million as of June 30, 2024, with a loss of approximately $46.874 million in the first half of 2024 alone [1][2]. Product Pipeline - The core products of Bokan Vision include CBT-001 and CBT-009, targeting pterygium and myopia in adolescents, respectively. CBT-001 has entered Phase 3 clinical trials in the US and China, while CBT-009 completed Phase 1/2 trials and is set to submit a new drug application to the FDA in July 2024 [1][6]. Patent and Regulatory Issues - CBT-001 is a modified new drug based on the active ingredient nintedanib, which is already approved for idiopathic pulmonary fibrosis. Bokan Vision holds a patent for using nintedanib to treat pterygium, but there are concerns about potential patent disputes, particularly with competitors like Allgenesis Biotherapeutics [3][4][5]. Commercialization Agreements - Bokan Vision has entered into exclusive commercialization agreements with Yuan Da Pharmaceutical and Santen Pharmaceutical, granting them rights to develop and market CBT-001 in various regions. The company expects to receive significant milestone payments and royalties based on sales [5]. Market Competition - CBT-009 faces intense competition in the myopia treatment market, with several companies already in advanced clinical stages. The efficacy of atropine for myopia control remains controversial, which may impact the product's market acceptance [6][7]. Challenges Ahead - Bokan Vision's lack of commercialization experience and the uncertainties surrounding its patent issues and product efficacy present significant challenges for its future development [7].

东莞证券指出，随着药品审评审批制度改革深化、医保动态调整机制完善，行业创新生态显著优化，标 志着我国医药创新正式进入"量质齐升"的成果兑现期，产业竞争力向全球价值链高端迈进。 中邮证券则坚定看好2-3年维度的创新药行情。首先是出海，较多优质项目BD虽已有一定市场预期，但 仍存在落地超预期的可能，且海外估值并未泡沫化，出海也已形成正向循环，未来全球看国内创新药比 例仍有提升空间；其次资金面目前宽基对创新药板块的配置远未见顶，且外资对港股创新药的配置也有 提升空间。 产业链和公司方面，据方正证券表示， 据人民财讯6月16日报道，国家药监局综合司公开征求《关于优化创新药临床试验审评审批有关事项的 公告（征求意见稿）》意见。 其中意见提出对符合要求的创新药临床试验申请在30个工作日（通常是60天）内完成审评审批。 今年年初政府工作报告涉及了多项医药行业重点政策，强调对创新药的支持力度显著提升。 1）仿转创企业的创新重估，仿转创企业大多已穿越集采周期影响，创新成果不断涌现，估值应当重 估，核心：华纳药厂、三生制药、石药集团/新诺威、中国生物制药、翰森制药、康哲药业、先声药 业、远大医药、舒泰神、一品红等； 2）强者恒强 ...

Industry Overview - The ophthalmic drug development sector is referred to as a "golden track," with opportunities to extend patent periods and develop new indications to maintain market dominance [1] - The global ophthalmic drug market has seen rapid growth, increasing from $32.4 billion in 2018 to $38.7 billion in 2022, and is projected to reach $57 billion by 2027 and $85.8 billion by 2032 [1] Company Profile - Cloudbreak Pharma Inc. (拨康视云) is a clinical-stage ophthalmic biotechnology company focused on developing various therapies [2][3] - The company has submitted its listing application to the Hong Kong Stock Exchange multiple times, with its latest submission on June 11 [2] - Cloudbreak Pharma has raised approximately $154 million across four funding rounds, with a post-Series C valuation of $469 million [2] Financial Performance - The company has reported cumulative losses of $295 million over three years, with annual losses of approximately $67 million, $129 million, and $99 million for 2022, 2023, and 2024, respectively [7] - The company anticipates increased losses in 2025 due to rising employee costs related to share-based payments [7] - Research and development expenses have been increasing, with figures of $15 million, $28 million, and $38 million for the respective years [9] Product Pipeline - Cloudbreak Pharma has developed a pipeline of candidate drugs, including two core products: CBT-001 for treating pterygium and CBT-009 for juvenile myopia [3][5] - CBT-001 is currently in Phase 3 multi-regional clinical trials in the U.S. and China, expected to complete by the end of 2025 [11] - The global market for pterygium treatment is projected to reach $273.4 million by 2027, with a compound annual growth rate (CAGR) of 56% [11] Commercialization Challenges - The company has licensed part of the rights for CBT-001 to a partner, which may expedite commercialization but could also reduce profitability for Cloudbreak Pharma [15] - The financial situation of the company is precarious, with increasing liabilities and negative cash flow from operations, necessitating external financing [9][10]

Group 1 - The Hong Kong stock market opened lower but the innovative drug sector led the gains, with significant increases in stocks such as China Biologic Products rising over 16% and Zai Lab rising over 10% [1] - The Hong Kong innovative drug ETF (159567) has seen a net inflow of funds over the past five trading days, indicating high market interest [1] - China Biologic Products has successfully deepened its innovation transformation, with the revenue share from innovative products increasing from 16% in 2018 to an expected 42% in 2024, and projected to exceed 50% by 2025 [1] Group 2 - The innovative drug ETF (159992) tracks an index that includes leading companies in the innovative drug industry, benefiting from trends such as AI-enabled drug development and the international expansion of domestic innovative drugs [2] - The innovative drug sector is showing significant investment value, with Chinese innovative drug companies gaining international competitiveness, as evidenced by 73 oral presentations at the 2025 ASCO annual meeting [2] - In the first quarter of 2025, Chinese innovative drug companies completed 41 overseas licensing transactions totaling $36.929 billion, indicating an accelerated internationalization process [2]

Core Viewpoint - The Hong Kong stock market opened lower on June 12, with the Hang Seng Index down 0.59% and the Hang Seng Tech Index down 1.13%, while the innovative drug concept opened higher against the trend [1] Group 1: Market Performance - The Hong Kong innovative drug ETF (159567) rose by 2.06% with a trading volume exceeding 200 million and a turnover rate over 11% [1] - On June 11, the innovative drug ETF (159567) experienced a significant net inflow of over 160 million [2] Group 2: Sector Insights - Pacific Securities suggests focusing on the pharmaceutical sector due to the impact of market pricing power and capital changes, particularly in innovative drugs, as liquidity and risk appetite have improved [2] - The upcoming AACR and ASCO conferences are expected to enhance the attention on innovative biotech catalysts, with domestic companies leading in dual-antibody ADCs, TYK2 inhibitors, GKA agonists, and pan-KRAS inhibitors [2] - Everbright Securities highlights the active participation and competitiveness of Chinese pharmaceutical companies in new drug development, especially following the ASCO annual meeting, which showcased impressive results and data [2]

Group 1 - The core viewpoint of the article highlights the strong performance of Hong Kong pharmaceutical stocks, particularly China Biologic Products, which saw a significant increase of 13.84% [1] - Other notable gainers in the pharmaceutical sector include Akeso, Inc. with a rise of 7.14%, and Wondfo Biotech, which increased by 4.43% [1] - The overall trend indicates a positive sentiment in the pharmaceutical industry within the Hong Kong stock market [1]

Group 1 - The core viewpoint is that the pharmaceutical sector is experiencing a phase of revaluation, particularly in innovative drugs, which is expected to continue in the long term [2][3][4] - The market has fully recognized the pessimistic expectations for the pharmaceutical sector, influenced by economic downturns and regulatory pressures, but it overlooks the innovation and technological aspects of the industry [3][4] - The Hang Seng Medical ETF (513060) tracks the Hang Seng Healthcare Index, which consists of 70% innovative drugs and their supply chain, indicating a focus on the recovery of innovative drug valuations and cyclical recovery [4] Group 2 - In the short term (1-3 months), the pharmaceutical index is expected to enter a phase of volatility, with a consensus on the revaluation of innovative drugs [2] - In the medium term (3-12 months), the outlook for the pharmaceutical index remains optimistic, as it is currently at a low valuation compared to historical levels [2][3] - The recovery potential for cyclical aspects of the pharmaceutical sector, such as medical devices and consumer healthcare, is significant as the economy stabilizes [3][4]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry [7] Core Insights - The report highlights that the Chinese innovative drug sector is poised to capitalize on the patent cliff faced by multinational corporations (MNCs), with a potential market space exceeding $240 billion due to the expiration of patents on 31 major drugs by 2037 [5][18] - It emphasizes that China has the largest number of innovative drug pipelines globally, particularly in cell therapy, ADCs, and bispecific antibodies, which positions it as a key player in the global market [5][32] - The report suggests that the ongoing trend of licensing out Chinese innovations to MNCs could lead to significant profit opportunities, estimating a net profit of approximately $8.2 billion from authorized projects between 2020 and 2025, translating to a potential market capitalization increase of $81.7 billion [5][46][47] Summary by Sections Market Review - The report notes that the CITIC Pharmaceutical Index rose by 1.2% during the week of June 3-6, 2025, outperforming the CSI 300 Index by 0.3 percentage points [4][48] - The pharmaceutical sector has shown a year-to-date increase of 8.3%, surpassing the CSI 300 Index by 9.9 percentage points [4][48] MNC Patent Cliff - The report identifies that 27 drugs with projected sales exceeding $4 billion in 2024 will face patent expiration by 2037, leading to a potential loss of approximately $244.3 billion for MNCs [18][19] - Specific drugs mentioned include Merck's Keytruda and Pfizer's Eliquis, which are expected to face significant sales declines post-patent expiration [19][20] Supply and Demand Dynamics - China leads globally in the number of innovative drug pipelines, particularly in cell therapy and ADCs, with 58% of these drugs currently in clinical phase I trials [32][33] - The report indicates that Chinese companies are involved in 716 research tracks, ranking first in development progress [32][33] Transaction Trends - The report highlights a significant increase in global pharmaceutical transactions, with the number of deals rising from 358 in 2015 to 743 in 2024, and total transaction value increasing from $56.9 billion to $187.4 billion [36][39] - Chinese companies accounted for 30% of global transaction value in 2024, with a total of $57.1 billion in deals [39][40] Investment Recommendations - The report suggests focusing on companies with strong overseas clinical progress and those with potential for significant licensing deals, including Innovent Biologics, Eddingpharm, and others [5][6] - It also recommends monitoring companies that have received approval for commercialization, such as BeiGene and Kingsoft Biopharma [5][6]

Core Viewpoint - The article highlights significant stock movements in the Hong Kong and US markets, indicating potential investment opportunities and sector trends, particularly in technology, healthcare, and entertainment sectors [1][2][3]. Hong Kong Market Highlights - Mixue (02097) surged over 7%, while Bluetec (00325) rose over 16%, and Guming (01364) increased over 3% [1]. - Lion Group (02562) gained over 4% as it plans to acquire a domestic SaaS company with substantial market share [1]. - Apple-related stocks saw a broad increase, with Sunny Optical (02382) up nearly 4%, and other companies like Q Tech (01478) and AAC Technologies (02018) rising over 3% [1]. - Far East Pharmaceutical (00512) rose over 3% as it commenced international Phase III clinical trials for its innovative ophthalmic drug CBT-001 [1]. - Alibaba Pictures (01060) jumped over 16%, with a cumulative increase of nearly 140% over the past two weeks, focusing on Damao performances and IP derivatives [1]. - Global Data (09698) increased over 5% after signing a strategic agreement with China Life Investment for comprehensive cooperation in asset securitization [1]. - Three Life Pharmaceuticals (01530) rose over 5% following a significant licensing agreement with Pfizer, showcasing promising data for SSGJ-707 [1]. - JD Group (09618) gained nearly 5% after signing a strategic cooperation agreement with China Resources Group [1]. - Tencent Music (01698) increased over 6% as it expands its international footprint by investing in South Korea's SM Entertainment [1]. - Cinda Biologics (01801) rose over 6% due to promising early data for IBI363 in lung cancer, with Goldman Sachs previously indicating the stock was undervalued [1]. - SMIC (00981) increased nearly 4% as it plans to sell its stake in SMIC Ningbo to focus on its core business [1]. - Rare earth stocks surged, with China Rare Earth (00769) up over 48% [1]. - Fubo Group (03738) rose over 3% after completing a 138 million share placement to enhance its AI business [1]. - Friendship Time (06820) surged over 22%, with a year-to-date increase exceeding 90%, driven by positive market feedback on its new game [1]. - Military stocks collectively rose, with China Shipbuilding Defense (00317) increasing nearly 4% [1]. US Market Highlights - Huaxing Capital Holdings (01911) surged over 14% following the successful listing of stablecoin "first stock" Circle, in which its fund participated in 2018 [2]. - In the US market, Circle's stock skyrocketed nearly 30% on its second day of trading after an initial 168% surge [2]. - Lululemon (LULU.US) fell nearly 20% after lowering its full-year profit guidance [2]. - DocuSign (DOCU.US) dropped nearly 19% after revising its full-year billing revenue forecast downward [2]. - Virgin Galactic (SPCE.US) rose over 2%, with a peak increase of over 14%, as it announced a potential recovery in commercial space flight services [2]. - Nvidia's holdings saw a broad increase, with Applied Digital (APLD.US) up over 8% and Recursion Pharmaceuticals (RXRX.US) rising over 20% [2]. - Robinhood (HOOD.US) fell 6.25% in after-hours trading, while AI stock Applovin (APP.US) dropped 5.53% [3].